View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 2, 2016updated 25 Mar 2022 7:51am

Infirst’s Granulox available for chronic wounds in NHS UK

Infirst Healthcare has revealed that Granulox is currently available on the National Health Service (NHS) Drug Tariff Part IX for UK patients suffering from non-healing wounds.

Infirst Healthcare has revealed that Granulox is currently available on the National Health Service (NHS) Drug Tariff Part IX for UK patients suffering from non-healing wounds.

The Granulox haemoglobin spray is said to increase oxygen levels at the wound bed, therefore increasing healing and reducing pain.

Infirst Healthcare CEO Manfred Scheske said: “This is very good news for UK patients who suffer from debilitating chronic wounds that severely affect their physical and emotional well-being.

“It is also good news for healthcare professionals and for the NHS to add a novel treatment option to standard therapy that promises significant patient benefits, as well as cost effectiveness.”

“This is very good news for UK patients who suffer from debilitating chronic wounds that severely affect their physical and emotional well-being.”

Nearly 200,000 patients in the UK are currently living with non-healing wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and post-surgical wounds.

More than 80% of the wounds are associated with venous insufficiency, high blood pressure or diabetes mellitus, leading to inadequate oxygen supply via the vascular system.

NHS spends up to £3.1 billion annually on treating such chronic wounds.

The costs associated with treating these patients include nursing time, dressings, hospital admissions, pain relief and frequent amputations.

Date from independent clinical studies revealed that, when added to standard care, Granulox could save the NHS an average of £2,330 for every diabetic foot ulcer patient and £1,469 for every chronic wound patient after six months.

The clinical efficacy and cost analysis data have also been reviewed and verified by the Scottish Health Technologies Group (SHTG), part of NHS Scotland.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology